To identify sources of inter-subject variation in vaccine responses, we performed high-frequency sampling of human peripheral blood cells post-vaccination, followed by a novel systems biology analysis. Functional principal component analysis was used to examine time varying B cell vaccine responses. In subjects vaccinated within the previous three years, 90% of transcriptome variation was explained by a single subject-specific mathematical pattern. Within individual vaccine response patterns, a common subset of 742 genes was strongly correlated with migrating plasma cells. Of these, 366 genes were associated with human plasmablasts differentiating in vitro. Additionally, subject-specific temporal transcriptome patterns in peripheral blood mononuclear cells identified migration of myeloid/dendritic cell lineage cells one day after vaccination. Upstream analyses of transcriptome changes suggested both shared and subject-specific transcription groups underlying larger patterns. With robust statistical methods, time-varying response characteristics of individual subjects were effectively captured along with a shared plasma cell gene signature.
To identify sources of inter-subject variation in vaccine responses, we performed high-frequency sampling of human peripheral blood cells post-vaccination, followed by a novel systems biology analysis. Functional principal component analysis was used to examine time varying B cell vaccine responses. In subjects vaccinated within the previous three years, 90% of transcriptome variation was explained by a single subject-specific mathematical pattern. Within individual vaccine response patterns, a common subset of 742 genes was strongly correlated with migrating plasma cells. Of these, 366 genes were associated with human plasmablasts differentiating in vitro. Additionally, subject-specific temporal transcriptome patterns in peripheral blood mononuclear cells identified migration of myeloid/dendritic cell lineage cells one day after vaccination. Upstream analyses of transcriptome changes suggested both shared and subject-specific transcription groups underlying larger patterns. With robust statistical methods, time-varying response characteristics of individual subjects were effectively captured along with a shared plasma cell gene signature. P andemic and seasonal influenza causes significant morbidity and mortality worldwide. A key strategy in preventing influenza infection is vaccination, which induces B cells to differentiate through several stages into plasmablasts and long-lived plasma cells. These cells produce protective antibodies (immunoglobulin) against hemagglutinin (HA) capsid proteins 1 . The World Health Organization (WHO) defines effective influenza vaccine responses as 28-day post-vaccine antibody hemagglutinin inhibition assay (HAI) titer $ 1540 2 . However, influenza vaccines produce highly variable B cell responses among individuals 3 , making it difficult to predict who will achieve protective antibody titers and when.
Advances in data-driven personalized medicine, as applied to vaccine immunobiology, require new statistical methods that are able to capture immune response features common across subjects (e.g. consensus gene expression patterns) and patient-specific patterns which differ between subjects. This is especially true in vaccine studies. For example, recent studies on transcriptome patterns in vaccine responses have used sparse sampling (i.e. microarray analysis of PBMC on days 0, 3, and 7), and analytic methods that do not involve time series analysis [4] [5] [6] . In this report, we describe a robust systems biology approach using functional principal component analysis to identify common and subject-specific time-varying gene signatures within the trivalent influenza vaccine (TIV) immune response.
In a memory response to influenza vaccination, resting memory B cells differentiate through proliferating plasmablast states to terminally differentiated non-proliferating plasma cells 7 . Migrating through peripheral blood to bone marrow and spleen, virus-specific antibody-secreting cells (ASC) appear 5-9 days post-vaccination 8 . Vaccine or influenza exposure induces memory B cells producing cross-reactive antibodies to similar influenza strains, termed heterosubtypic immunity 9 . The presence of heterosubtypic immunity alters the speed and strength of TIV responses. Previous systems biology vaccine response analyses have sampled subjects on a single day empirically described as the peak B cell response 10, 4 . Such approaches lack the structure to capture peak responses or the statistical power to separate time varying gene signatures from inter-subject variation. Our approach is fundamentally different. Our goal was instead to identify differences in the character of the tran- scriptome responses of individuals using high-frequency sampling and an analytical method designed to characterize temporal patterns in complex systems. In contrast to other studies 10, 4 , we were not trying to predict who responded to the vaccine. Rather, our goal was a deeper understanding of the time varying, vaccine specific, transcriptome response, and to determine if the B and plasma cell gene expression patterns varied as a function of pre-existing vaccine antigen memory. Systems analysis of high-frequency time course data requires more samples per subject, but better defines peak and time varying B cell immune responses.
To separate concensus from subject-specific time-varying B cell transcriptome responses to influenza vaccination, we performed high-frequency (daily) sampling of serum, peripheral blood mononuclear cells (PBMC), B cells and plasma cells from 14 human subjects over 11 days post-TIV administration. Our approach combined time-series transcriptome analysis, flow cytometry, ELISPOT, ELISA, and HAI assays with computational analysis to identify time-varying RNA biomarkers associated with robust B cell responses. To identify subject-specific gene expression signatures, we used functional principal component analysis (FPCA), a statistical dimension reduction method for high frequency time series data similar to principal component analysis for single time-point data 11, 12 . In essence, the differential expression of each gene is determined by its own signal-tonoise ratio. The major temporal variation in the RNAseq time-series data can be characterized by a few representative patterns called eigenfunctions. Each gene expression curve is approximated by a linear combination of these eigenfunctions, enabling a flexible and parsimonious representation of time-series data. This method accommodated individuality in vaccine response by identifying time-varying transcriptome patterns unique to each subject. For a detailed explication of FPCA, and underlying statistical theory, please see the specific section in Supplementary Methods. This approach identified a peripheral blood B cell transcriptome signature in previously vaccinated subjects that was strongly correlated with migrating plasma cells observed with cytometry. Upstream analysis of significant gene sets revealed common immunological dynamics between subjects as well as unique vaccine response features in individuals. At the subject level, these responses were associated with robust protective antibody responses and a prior history of influenza vaccination. Eigenfunctions calculated for PBMC gene expression also demonstrated an early wave of myeloid/dendritic cell lineage migration peaking 24 hours post-vaccination. Additional eigenfunctions identified transcriptome changes unique to each individual, commonalities between subject-specific signatures, and their relative contribution to the overall vaccine response.
Results
Heterogeneous antibody responses to TIV vaccination. We vaccinated three cohorts of 3-6 subjects (n 5 14 subjects) with the 2010-2011 TIV. Subjects reported mixed vaccine histories, with two subjects reporting no influenza vaccination in three consecutive years prior to the study, and three subjects reporting receiving all available influenza vaccines. Two of study vaccine strains, A/ California/7/2009 and B/Brisbane/60/2008 were included in recent vaccines (Supplementary Table S1 ).
For analysis, peripheral blood was drawn during the week prior to vaccination (pre-V), immediately before vaccination (day 0), daily for days 1-10 and on day 21 post-vaccination. HAI and isotypespecific ELISA assays were performed on serum samples. (Fig. 1,  Supplementary Fig. S1 ). No two subjects had identical changes in HAI titers. One subject had no pre-vaccine immunity (HAI , 1540), and five subjects had pre-vaccine immunity (HAI $ 1540) to all three viral strains (Fig. 1, Supplementary Table S2 ). At day 21, all 14 subjects had immunity to A/California, 12 had immunity to A/ Perth and 13 had immunity to B/Brisbane. Differences in gene expression correlate with vaccine history and response. B cell samples (days 0-10) were analyzed by RNAseq, flow cytometric and ELISPOT (880 samples) ( Supplementary Fig. S1 ). Due to cost, RNA Seq analysis was performed on PBMC and B cell enriched samples from one contemporaneous cohort of five subjects, days 0 to 10 (110 samples). S01 RNA was used for RNA Seq pilot studies. We selected a single cohort of subject samples for RNA Seq analysis. Each gene was tested for differential change from day 0 to day 10 using FPCA-based significance testing 13 and a permutation test coupled with multiple-testing correction to control the false discovery rate (FDR , 0.05) 14 . A deviation in a gene expression Pre-V With immunity classified as an HAI titer . 1540, S06 was not previously immune to any of the three viruses. S05, who had reported not being vaccinated in the previous three years, was immune to A/California only. S01, S07, and S10 were initially immune to all three viruses and the other subjects showed a mix of initial immunity. At day 21, all subjects except S08 and S12 qualified as immune. See also Supplementary Figure S1 and Supplementary Tables S1 and S2. curve from a flat line indicates a significant temporal pattern in transcriptomic variation.
Intra-subject variation in differentially expressed genes was moderate (p-values in Supplementary Table S3 ). S02 had the largest number of significantly time-varying genes (5580 genes) while S06 had few (2 genes). For better comparison with other subjects, 1600 genes with the highest signal to noise ratio were added to the analysis of S06. After excluding genes with less than a 1.2-fold-change from baseline, the numbers of temporally differentially expressed genes still varied greatly: S02 (5256 genes), S03 (1309 genes), S04 (2147 genes), S05 (1603 genes) and S06 (1053 genes). Notably, 742 genes were common to three of five subjects.
We next used FPCA to identify the major variations in temporal RNA expression patterns of the differentially expressed genes for each subject, which were then represented by eigenfunctions (Fig. 2a , complete list of significantly time-varying genes in Supplementary Table S3 ). For three subjects (S02, S03, S04), 90% of transcriptome variation could be accounted for by a single eigenfunction. All three of these subjects had a previous history of influenza vaccination, pre-vaccine immunity to at least one viral vaccine strain by WHO criteria, and strong antibody responses by HAI titer (Fig. 2b , p-values in Supplementary Table S2 ) and vaccine-specific ELISA (Fig. 2c , p-values in Supplementary Table S2) .
Cellular responses were seen by FACS in the appearance of vaccine-specific ASC (Fig. 2d) Supplementary Fig. S2 ), we found secretion-rate profiles typical of activated ASC 15 , with high-rate vaccine-specific IgG-secreting cells appearing at peak responses.
Subject-specific dynamics were seen in vaccine response characteristics at multiple levels. S02 had a sharp peak in cellular and RNA changes at day 5, whereas S03 and S04 had more gradual changes. These subjects met serum and cellular criteria for robust memory B cell responses to TIV. However, with some evidence of de novo reactivity to A/California, and without specific clone data, we prefer the term ''predominantly recall'' responses.
In two subjects (S05, S06), 90% of the variation in gene expression could be explained by two eigenfunctions, indicating two distinct temporal patterns of gene expression. S06 had a linear trend in some genes and S05 had multimodal eigenfunctions. These subjects reported no influenza vaccination in the previous three years and developed de novo immunity to at least two vaccine-specific viruses by WHO HAI criteria. Acknowledging the difficulties in defining an influenza response in adults as truly naive, we prefer the term ''predominantly de novo'' responses.
Taken together, results from the high frequency sampling data show coordinated and dynamic vaccine-response changes at serum, cellular, and transcriptomic levels, as well as inter-subject variations in immunological response characteristics. Features of time-varying transcriptome profiles independently identified subjects with significant pre-vaccine B cell memory. Also, high-frequency sampling provided the resolution to discern unique expression dynamics across assays for each subject.
Transcriptome changes in the B cell predominantly recall response were consistent with late B cell differentiation. To connect the transcriptomic and cellular level B cell influenza vaccine responses, we hypothesized that predominantly recall TIV responses would be characterized by significant variations in established markers of late B cell differentiation (Fig. 2f ). Detailed analysis showed known genes with time-varying patterns that paralleled B cell phenotypic changes in S02, S03 and S04 including the genes for CD70 receptor CD27 [16] [17] [18] , ecto-enzyme CD38 16 , plasma cell marker syndecan-1 (SDC1 or CD138), and genes encoding regulatory molecules PRDM1 (Blimp-1) 19, 7 , IRF4 16,20,21 and XBP1
22
. Also increased was CD59, which has been associated with memory B cell differentiation 23 . Increased expression of CXCR3, a gene for a migration marker 24 suggested trafficking from the germinal center through peripheral blood presumably to bone marrow and spleen. Decreases in MS4A1 (CD20) and CD19 at peak cellular changes are also consistent with late-stage differentiating B cells 16, 25, 26, 23 . PAX5 7 and BACH2 27 are known repressors of B cell differentiation and decreased gene expression has been linked to expression of PRDM1
28
. In subjects with predominantly de novo responses (S05, S06) time-varying expression of these differentiation markers was modest or absent.
Decreases were seen at peak response in CD5, the gene expressing a marker of naïve B cells, and SERPINB9 (PI-9), an enzyme that protects cytolytic B cells from endogenously produced granzyme B 29 . It has been proposed that a granzyme B expressing cytolytic B cell lineage diverges from plasmablasts during differentiation 30 .
Reduced expression of these markers may reflect ASC fractional expansion post-vaccination.
To confirm and validate changes in expression of key B cell differentiation genes, we probed RNA samples of the eight other subjects by qRT-PCR for 11 genes: SDC1, IGHG, XBP1, CD27, CD38, CD59, PRDM1, IRF4, IRF8, BACH2, and PAX5. These subjects were heterogeneous in vaccine response by HAI titer (Fig. 3a) , vaccinespecific ELISA (Fig. 3b) , and flow cytometry (Fig. 3c ). Changes in migrating B cells and plasma cells over time exhibited a similar pattern in these independent subjects ( Fig. 3d and Supplementary  Table S5) .
A strong gene expression signature post-TIV in previously vaccinated subjects is associated with migrating plasma cells. In comparing significant time-varying gene sets between individuals, we found a biomarker signature of 742 genes common to predominantly recall subjects (Fig. 4 Supplementary Table S6 ). These associations were strong in all three subjects, even though the timing of peak expression, and composition of genes within the broader significant gene sets, varied between subjects. We refer to this set of 742 genes as the plasma cell gene signature (PCgs). hi plasmablasts (Fig. 5b ) (n 5 6 subjects). We hypothesized that a subset of PCgs genes would be differentially expressed between the CD27 lo (proliferating but non-IgG secreting) B cell and the more differentiated CD27 hi plasmablasts (Fig. 5c ). Of 2033 genes differentially expressed between CD27 lo and CD27 hi B cells, 366 genes of the PCgs were highly expressed in the CD27
Expression of the
hi plasmablasts (Fig. 5d , full gene list in Supplementary  Table S6 ). These independent findings strengthen the association between the PCgs and differentiating plasma cell subtypes (Fig. 5e) . Common upstream regulatory mechanisms in the PCgs. Given the strength of the in vivo and in vitro associations between the plasma cell population kinetics and the PCgs at the gene level, it seemed likely that there were common upstream regulatory transcription factors. We performed upstream analysis on gene expression data from S02 using IngenuityH Pathways Analysis (IPA). Fisher's exact test was used to assess overlap between the data set and curated gene sets associated in the literature with upstream modulators Table S3 ). CD5 and SERPINB9 levels decrease at peak response consistent with a fractional decrease in naïve and cytolytic B cells. Fewer genes changed significantly in S06 and S05, subjects reporting no vaccination in the previous 3 years. S02 showed peak response at day 5, earlier than S03 and S04. (N/D 5 no data). (www.ingenuity.com). We constructed a time series movie of a network of identified upstream modulators (p-value , 0.01) and their targets, (see Supplementary Movie S1). Gene expression changes consistent with release of suppression of B cell regulator PRDM1 (Blimp1) by BACH2 27 occur by day 4. In days 4 through 10, upregulation of XBP1 was seen, as well as downstream genes associated with ER function, the unfolded protein response, protein production and transport. We also performed functional enrichment analyses of Gene Ontology (GO) terms using DAVID (http://david.abcc. ncifcrf.gov/) and analyses of pathways with KEGG, BIOCARTA and REACTOME (Supplementary Table S7 ). Ten of the top 30 categories of functionally related genes in the PCgs involved ER function and protein production. These findings are consistent with involvement of the PCgs in program-level upregulation of antibody production machinery and the unfolded protein response seen during plasma cell development 28 .
Unique as well as shared B cell response features beneath the larger patterns. In addition to the common PCgs, each subject had unique time-varying gene sets. We hypothesized that these may reflect differences between subjects in regulatory transcription factors. Using the complete set of significant genes for each predominantly recall subject, upstream analysis identified a likely set of upstream activators (Z-score . 2.0) that spanned the peak B cell response in all three subjects (Fig. 6) . IL2, IL4, IL5, IL6 and CD40 ligand were identified as probable activators. While the signaling pathways of these activators are not mutually exclusive, this is consistent with a plasma cell history of germinal center reaction.
In addition to common upstream activators, each subject also had a unique set of significantly varying transcription factors. Of particular interest, a wave of probable activation of Type I IFN and IFN-related gene sets appeared in S04 two days after the shared germinal center pattern. This could be evidence of a secondary migration of B cells with previous plasmacytoid dendritic cell (pDC) interaction within the broader peak response. Producers of large amounts of Type I Interferons, pDC are part of the innate response to virus and can induce antibody production by CD40-stimulated B cells in response to influenza 31, 32 . As interferon regulatory factor (IRF) proteins can also regulate B cell differentiation in response to toll-like receptor stimulation 33, 34 , another interpretation of this pattern is a viral DNA-initiated innate response to the vaccine. The eigenfunctions derived by the analysis, along with upstream analysis, identified both common and subject-specific dynamic gene sets that may represent the effects of interacting innate and adaptive cellular immune systems on differentiating plasma cell.
Myeloid cell gene signatures peak in PBMC primary eigenfunctions at Day 1. We next hypothesized that the PCgs could be identified in PBMC collected in parallel with the B cell samples. We found something quite unexpected. The primary eigenfunction in the RNA Seq gene expression data, which explained over 70% of the variation for four out of five subjects (S02, 81.44%; S03, 86.68%; S04, 72.8%; S05, 57.15%; S06, 85.32%), peaked on day 1 postvaccination (Fig. 7a) . In the predominantly recall subjects, the genes with largest positive loadings on the primary eigenfunction were enriched for myeloid/dendritic cell (DC) lineage-associated genes (Fig. 7b, Supplementary Table S8) . Interestingly, the first eigenfunctions for predominantly de novo response subject S06 also contained myeloid/DC genes with more modest overall gene expression changes. These results suggest that even within the far more complex and dynamic mix of cellular populations in post-vaccination PBMC, FPCA analysis could identify a wave of myeloid lineage cells released into peripheral blood one day postinfluenza vaccination in four of five subjects.
Discussion
Using a method based on FPCA for time-series transcriptome analysis, we identified a 742 gene signature, upstream transcription factors, and subject-specific gene sets associated with a robust B cell response to influenza vaccine. The method yields quantitative functions (eigenfunctions) that describe the temporal pattern of major transcriptome variation. In previously vaccinated subjects, the 742 gene signature was highly correlated with the migration of differentiating plasma cells through peripheral blood. There was an association between the PCgs and key upstream transcription factors that control antibody production including PRDM1 and XBP1. A second gene signature was identified in unfractionated PBMC with a transcriptome profile suggesting migration of cells of the myeloid/ DC lineage one day post-vaccination. In addition to these common gene signatures, eigenfunctions identified specific points of variation between individuals including a late spike in IFN-related gene activity. Thus, this approach can identify processes common across individuals in a vaccine response, as well as unique features that may underlie variation between subjects. A systems biology approach to studies of B cell response requires not only connections between nested levels of regulation from genes to the whole organism, but also perturbations in these systems over time. This study was designed to capture frequent and complete B cell gene expression dynamics after influenza vaccination in a small set of subjects. In this study, high-frequency data from each subject serves as an intra-subject control, adding statistical power and accuracy for detection of significant signals from noisy transcriptome data. A better understanding of vaccineinduced subject-specific gene dynamics may help design studies with more subjects and fewer timepoints that still capture transcriptome patterns. ATF4  ANGPT2  CD38  CD40LG  IL2  IL4  IL5  IL6  IL7  ERN1  NFE2L2  SP1  F2  LPS  TGFB1  THBS4  SYVN1  XBP1   A2M  CEBPA  CEBPB  E2F1  EP400  HGF  IGF1R  IL21  Ins1  MYC  NKX2-3  RAF1  TBX2  TNFSF11  VEGFA  BRCA1  IL3  Ras  TFEB   S03  S04   1  7 1 0  4   ACTB  AGT  BMP4  CD24  CTNNB1  E2F2  E2F3  EDN1  EIF4G1  ERBB2  ERBB4  FOXA1  FOXM1  FOXO1  GADD45A  GATA1  HRAS  IGF1  IL13  KLF5  mir-132  MTPN  MYB  MYBL2  NFKBIA  NFYA  PIM1  S100A6  SMOC2  STAT6  TLX1  TNFSF13  TP63  WT1   Unique to S03   EIF2AK2  IFIH1  IFNA1/IFNA13  IFNA16  IFNA2  IFNAR1  IFNB1  IFNE  IFNK  IL1B  IRF1  IRF3  IRF5  IRF7  JAK1  NFkB (complex) poly rI:rC-RNA STAT1 STAT2 STAT3 STAT4 TLR3 TNFSF10 miR-1205 miR-149-3p miR-27a-3p miR-30c-5p miR-4514 miR-516a-3p miR-663b  ANXA7  CREB3L2  DDX58  EIF2AK3  ESR1  ETS1  HIF1A  IKBK  IL29  LDL  melatonin  NFATC2  OSM  PAF1  PDGF BB  PLK2  PMA  PTPRJ  SASH1  SP3  TGM2  ATF6  BAK1  BAX  IFNG  IL15  IL24  JUN  MYD88  NRF1  PPARG  PRNP  SAMSN1  SKIL  TICAM1  TP53  AHR  CSF2  EPO  ESRRA  GLI1  IL10  INSR  NR3C1  PARK2  THRB  TRAF3 Molecule sets downstream of these modifiers were not mutually exclusive. All three subjects showed probable activation by upstream cytokines typical of the germinal center reaction, including IL2, IL4, IL5, IL6 and CD40LG across days of peak response. Upstream modifiers unique to each subject suggested immunological differences. Of interest, late in the peak response of S04, IFN-related signaling molecules were identified. This could be the result of a previous innate-type stimulus such as interaction with plasmacytoid dendritic cells or viral DNA-initiated toll-like receptor activation. Our method identified dynamic gene regulation patterns with common as well as subject-specific upstream regulatory elements underlying the larger post-vaccine response. LYZ  VCAN  AHNAK  CTSS  MPEG1  FCN1  LRP1  FGL2  CYBB  ACTB  APLP2  KCTD12  CD14  SRRM2  CCR2  AKAP13  CPVL  TGFBI  DMXL2  SERPINA1  TLR4  XIST  GAS7  CD300E  FTL  MYCBP2  SPTLC2  ZEB2  IRAK3  SULF2  ANXA5  SLC7A7  VPS13C  TLR2  DICER1  MACF1  LRRFIP1  CFP  IFNGR1  TIMP2  MLL3  CORO1C  MARCH1  S100A6  ADRBK2  ZMIZ1  BACH1  TET3  PRRC2C  ATP11A   PSAP  CTSS  CYBB  FCN1  LRP1  SERPINA1  IFI30  COTL1  TNFAIP2  FGR  GRN  CX3CR1  HLA-DPA1  IQGAP1  NOTCH2  TNFRSF1B  HLA-DRB1  WARS  ITGAX  PLXNB2  CSF1R  SAMHD1  CD68  ITGAM  LYN  HCK  TGFBI  GNS  CPVL  DMXL2  MS4A6A  CD300E  TKT  PLEK  CECR1  TPP1  PPT1  SH3BP2  HLA-DQB1  TYMP  STAB1  IL17RA  PIK3AP1  AOAH  CD97  NFAM1  LILRB2  LTA4H  HK3 CTSS  VCAN  CD74  ACTB  FGL2  FCN1  HLA-DRA  CYBB  S100A9  MPEG1  LCP1  FTL  ITGB2  LRP1  IFI30  SERPINA1  COTL1  TNFAIP2  GRN  APLP2  HLA-DPA1  FGR  TNFRSF1B  VIM  CTSB  CD68  CECR1  HLA-DRB1  KCTD12  NCF2  TKT  MSN  CD93  NOTCH2  DUSP6  TYMP  PLXNB2  LTA4H  FTH1  CD14  LYN  HLA-DPB1  CD36  SAMHD1  C10orf54  DMXL2  CSF1R  ATP6V1B2   FLNA  HLA-C  PLEC  HMHA1  CORO1A  ITGB2  SEPT9  AKNA  ADRBK1  ARHGAP4  FMNL1  MYO1F  TNFAIP2  TCIRG1  LIMD2  PIK3CD  NUMA1  HLA-F  SBF1  TBC1D10C  ALDOA  ARAP1  NOTCH1  ZYX  LRCH4  MYO9B  FAM38A  ARHGDIA  FTL  MYO1G  LRP1  PTPN6  POLR2A  CCDC88B  LTB  CYBA  PARP10  ABCA7  PKN1  PLCB2  FGD3  EFHD2  NCOR2  FKBP8  SLC9A3R1  RPL29  RNF44  SRCAP  UNC13D  TNK2   LYZ  PSAP  VCAN  CTSS  CYBB  MPEG1  FGL2  ITGB2  FCN1  LRP1  IFI30  S100A8  SERPINA1  GRN  COTL1  TNFRSF1B  KCTD12  FGR  APLP2  CX3CR1  CD68  CD14  CTSB  DUSP6  STAB1  C10orf54  CTSD  TNFAIP2  PLXNB2  CSF1R  CPVL  CD93  CD300E  TGFBI  GNS  ITGAM  WARS  TYMP  LTA4H  HCK  C1orf38  ZEB2  TYROBP  PIK3AP1  LYN  FCER1G  MS4A6A  CD36  CST3 (a) FPCA analysis of RNA Seq data showed a primary eigenfunction that explained over 70% of the variation across the timepoints for four subjects (S02, 81.44%) (S03, 86.68%) (S04, 72.8%) (S05, 57.15%) (S06, 85.32%). Second eigenfunctions explained most of the remaining variation in three subjects (S02, 13.11%) (S03, 7.24%) (S06, 10.2%). S05 had a third eigenfunction that explained 13.85% of variation. The first eigenfunction for S02, S03, and S04 peaked day 1. (b) The largest positive loadings on these functions were enriched for genes expressed by myeloid/DC lineages (gene symbols in red), (Supplementary Table S8 ). The first eigenfunction for S05 had few myeloid/DC genes. Second and third eigenfunctions, peaking day 1, both contained small numbers of myeloid/DC genes. The first eigenfunction of S06 peaking on day 1 was enriched for myeloid/DC genes, but expression changes were modest. Day 8 there was a sample processing error. The use of eigenfunctions to identify common patterns of gene expression that explain transcriptome variations is a powerful analytic method. Inter-subject vaccine response heterogeneity is considerable 3, 9, 4 . To generalize conclusions, other systems biological studies have averaged gene expression data across subjects 10 or restricted their analyses to significant genes shared in at least 20% of subjects 4 . Our goal was not to predict vaccine efficacy in large groups of people and indeed, all of our subjects achieved protective HAI titers. Our goal was to identify differences between the vaccine responses of individual subjects over time, and to identify dynamic gene expression mechanisms that underlie those differences. Our method approached subject variation by identifying subject-specific timevarying transcriptome signatures and within those unique patterns, identifying a B cell response gene set shared among individuals. This approach may yield more robust insights into immune response dynamics than sampling at wide time intervals (e.g. only days 0, 4 and 7 post-vaccination), which misses critical events in the individual response. While other studies have found plasma cell associated genes upregulated on Day 7 6, 4 , we found subject-specific variation in peak expression of PCgs that would have been missed with typical interval sampling.
Using high-frequency sampling, we found that subjects that had been previously vaccinated each had individual response characteristics, but 90% of the gene expression variation over time could be accounted for by a single subject-specific eigenfunction containing a common plasma cell transcriptome signature. This gene signature was identical in all three of the previously vaccinated subjects. As our sample size is small and all of our subjects for RNA Seq achieved protective HAI titers for the vaccine antigens, it is difficult to compare vaccine efficacy with incidence of the PCgs. One interpretation suggested by our findings is that the predominantly recall influenza vaccine responses exhibited a synchrony of B cell differentiation across vaccine-specific memory B cell populations, while the predominantly de novo responses did not. In combination with stochastic nature of plasma cell fate determination 35 , this synchrony of initiation likely resulted in a wave of differentiating plasma cell migrating from the germinal center of individuals with B cell memory.
PBMC eigenfunctions contained a signature suggesting migration of myeloid/DC lineage cells 24 hours after vaccination. Our results are quite consistent with a recent study using transcriptional analysis of whole blood after influenza vaccination 5 . In this study, neutrophils and monocytes were implicated as the major source of the IFNrelated gene set upregulated within 15 hours post-vaccination for influenza. Interferon-related transcripts upregulated one day after Influenza vaccination in an earlier study were also correlated with anti-Influenza antibody titers 6 . This myeloid/DC gene signature likely triggers the initial germinal center reaction that results in plasma cell migrations later.
At the organ level in normal human subjects, we cannot sample lymph nodes and spleen. However, our analysis suggests that with higher temporal transcriptome resolution, peripheral blood does reveal evidence of prior upstream gene regulation, reflecting hidden dynamic events within lymphoid compartments. Also, upstream transcriptome analysis revealed that migration of multiple B cell populations underlie broader B cell and plasma cell surface marker phenotypes observed by flow cytometry. Further detailed experiments are needed to determine if transcriptome patterns observed are from broad changes in B cell population cell frequencies or a single dominating subpopulation. Given that our PBMC analysis reflects mixed and dynamic cell populations, any resulting gene interaction network cannot be considered strictly causal, but rather should be interpreted as a network of temporally associated transcriptome changes, likely occurring in several cell populations. Further and more detailed cell sorting work will need to be done to validate this hypothesis.
At the cellular level, division-linked B cell differentiation 36, 37, 38 is asymmetric with key control molecules like BCL-6 bequeathed to one daughter cell 39 . This, along with graded IRF4 expression 21 , is thought to affect diversification of B cells. Our findings suggest that even with diverse B cell fates, a common transcriptomic signature can identify pre-existing vaccine-specific B cell memory, likely a marker for heterosubtypic immunity. During a pandemic, the PCgs may be useful in early prediction of both successful vaccine responses and heterosubtypic immunity.
At the individual gene level, within the PCgs we identified key plasma cell regulatory genes including those seen in other systems biology studies. TNFRSF17
10 was found in both in vitro and in vivo data sets, and XBP1 4,40 was central to our networks. Our highfrequency sampling extends these observations with detailed timeseries data capturing individual response patterns. Other genes previously associated with the post-vaccination neutralizing antibody response include KBTBD7
10
, which did not significantly change. We also found more genes specifically associated with plasma cells than previous studies. Whether this difference is due to the statistical strength of high-frequency sampling and FPCA, or other methodological differences, will be addressed in future studies.
Finally, we would like to note that FPCA-based time-series transcriptome analysis extends beyond simple statistical analysis. The method of FPCA and the form of the results are well suited for application to machine learning in computational modeling 41 . In replacing instinctive or heuristic approaches with a rigorous mathematic method that can approximate behaviors of a complex biological system, FPCA lends itself to the utilization of artificial intelligence methods in models and systems biology analyses. Specifically, the resulting eigenfunctions and matrix formulations allow more rigorous characterization and modeling of complex cellular and transcriptome responses.
In conclusion, these data provide evidence for a novel transcriptomic signature associated with differentiating B cell and plasma cell migration through peripheral blood B cell pools in subjects previously vaccinated for influenza. They also suggest that with further study, temporal transcriptome patterns that accommodate individual variation may illuminate more detailed system dynamics underlying large-scale responses. The method of FPCA may also allow robust modeling and systems analysis of immune responses using artificial intelligence and machine learning methods.
Methods
Human subjects protection. This study was approved by the Research Subjects Review Board at the University of Rochester Medical Center. Informed consent was obtained from all participants. Research data were coded such that subjects could not be identified, directly or through linked identifiers, in compliance with the Department of Health and Human Services Regulations for the Protection of Human Subjects (45 CFR 46.101(b)(4)). Subject identification numbers were re-encoded for publication.
Myeloma cell culture. Myeloma cell lines were maintained in log-phase growth as previously described 42 and used for controls in flow cytometry and ELISPOT assays: MPR-1130 (established in our laboratory), MC/CAR, Ramos cell lines (ATCC, Manassas, VA), NCI-H929 (ATCC, Manassas, VA).
Peripheral blood mononuclear cell (PBMC) isolation. Each daily blood sample for each subject was pooled from heparinized blood collection tubes and a portion removed for PBMC analysis. Lymphocytes were isolated using discontinuous Ficoll gradient centrifugation from buffy coat samples. Magnetic anti-CD235 immunoaffinity beads (Miltenyi Biotec, Auburn, CA) were used to remove RBC contaminants.
B cell isolation. B cell samples were enriched from heparinized whole blood with RosetteSep Immunodensity separation (Stemcell Technologies, Vancouver, BC, Canada). Negative magnetic immunoaffinity bead separation columns (Miltenyi Biotec, Auburn, CA) were used with anti-CD3 (BD Bioscience, San Diego, CA) and anti-CD235 beads (Miltenyi Biotec, Auburn, CA) to further purify total B cells. Flow cytometric analysis was performed on all isolates, showing .90% purity of the isolates.
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Flow cytometric assay. Data was collected as previously described 43 with FACS Diva data acquisition software on an LSR II cytometer. Analysis of data utilized Flowjo software (Treestar, Ashland, OR). Antibodies used included anti-CD138-APC, anti-CD20-V450 (BD Bioscience, San Diego, CA), anti-CD19-PE-Texas Red, anti-CD27-PE-Cy5, (Beckman Coulter, Indianapolis, IN), anti-CD38-PE-Cy7 (eBioscience, San Diego, CA), anti-CD3-PECy5.5 (Southern Biotech, Birmingham, AL), anti-B7-FITC (Santa Cruz Biotechnology, Santa Cruz, CA), anti-CCR10-PE (Biolegend, San Diego, CA), anti-CD62L-APC-Alexa-750, and Live/Dead Aqua (Invitrogen, Grand Island, NY).
Flow cytometry analysis. Before analysis with Flow clustering without K (FLOCK) software (https://immport.niaid.nih.gov), compensation and initial gating to remove debris and dead cells was competed using FlowJo (TreeStar). Files for each subject were then concatenated, uploaded to ImmPort and analyzed using FLOCK 1.0 44 to identify centroids for representative clusters across the timepoints. The following markers were used: CD19, CD20, CD138, CD3, CD27, CD38, B7, CCR10 and CD62L. Individual timepoint sample files were then analyzed against the centroids file, assigning all events to a cluster, using the Cross Sample Comparison feature of Flock. A semi supervised clustering method was used to cluster centroids to identify non-B cells (CD192, CD32), T cells (CD192, CD31), naive B cells (CD191, CD32, CD201, CD272), memory B cells (CD191, CD32, CD201, CD271), plasmablasts (CD191, CD32, CD202, CD1382) and plasma cells (CD191, CD32, CD202, CD1381). Percentages of each phenotype were calculated for each sample.
Hemagglutinin inhibition analysis (HAI). Hemagglutinin assays were performed as previously described 45 using the 2012-2011 WHO Influenza reagent Kit for identification of influenza isolates (WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza) and the Seiken method to remove nonspecific inhibitors of hemagglutination.
